P.A.W. Capital Corp Has $1.70 Million Stake in InMode Ltd. (NASDAQ:INMD)

P.A.W. Capital Corp cut its holdings in shares of InMode Ltd. (NASDAQ:INMD - Free Report) by 28.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 100,000 shares of the healthcare company's stock after selling 40,000 shares during the quarter. InMode makes up 3.8% of P.A.W. Capital Corp's investment portfolio, making the stock its 10th largest holding. P.A.W. Capital Corp owned 0.12% of InMode worth $1,695,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in INMD. Asset Dedication LLC bought a new position in InMode during the second quarter valued at $33,000. Headlands Technologies LLC increased its holdings in InMode by 118.2% in the 1st quarter. Headlands Technologies LLC now owns 1,916 shares of the healthcare company's stock worth $41,000 after acquiring an additional 1,038 shares during the last quarter. nVerses Capital LLC bought a new stake in InMode in the 2nd quarter valued at about $42,000. Nisa Investment Advisors LLC lifted its holdings in InMode by 314.7% during the third quarter. Nisa Investment Advisors LLC now owns 3,550 shares of the healthcare company's stock valued at $60,000 after purchasing an additional 2,694 shares during the last quarter. Finally, EMC Capital Management bought a new position in InMode during the first quarter worth about $90,000. 68.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on INMD shares. Canaccord Genuity Group reduced their price target on InMode from $21.00 to $16.00 and set a "hold" rating for the company in a research report on Friday, July 12th. Needham & Company LLC reissued a "hold" rating on shares of InMode in a report on Thursday. Barclays cut their price objective on shares of InMode from $29.00 to $27.00 and set an "overweight" rating for the company in a research report on Monday, October 14th. BTIG Research initiated coverage on InMode in a report on Thursday, October 17th. They set a "buy" rating and a $25.00 price objective on the stock. Finally, Jefferies Financial Group lowered InMode from a "buy" rating to a "hold" rating and cut their target price for the stock from $21.00 to $19.00 in a research note on Tuesday, July 23rd. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, InMode currently has an average rating of "Hold" and a consensus target price of $22.60.

InMode Trading Up 1.1 %

Shares of NASDAQ:INMD traded up $0.18 on Friday, reaching $17.26. 840,613 shares of the company traded hands, compared to its average volume of 1,146,337. The stock has a market capitalization of $1.45 billion, a P/E ratio of 9.33 and a beta of 2.15. The business's 50-day simple moving average is $16.65 and its 200 day simple moving average is $17.34. InMode Ltd. has a 52 week low of $14.87 and a 52 week high of $26.80.

InMode (NASDAQ:INMD - Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The healthcare company reported $0.34 EPS for the quarter, missing analysts' consensus estimates of $0.38 by ($0.04). The company had revenue of $102.60 million during the quarter, compared to analysts' expectations of $104.81 million. InMode had a return on equity of 21.46% and a net margin of 36.26%. InMode's revenue for the quarter was down 24.6% on a year-over-year basis. During the same period last year, the firm earned $0.65 earnings per share. Sell-side analysts expect that InMode Ltd. will post 1.58 EPS for the current fiscal year.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.